ID
Bron
Verkorte titel
Aandoening
EN: red blood cell transfusion, clearance, microcirculation, sepsis, intensive care medicine
NL: rode bloedcel transfusie, klaring, microcirculatie, sepsis, intensive care
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Phosphatidylserine exposure on donor RBCs
Achtergrond van het onderzoek
Inclusion are going to take place in the Academic medical centre, Amsterdam, the Netherlands
Onderzoeksopzet
Before transfusion and 1, 24 hours and 48 hours after transfusion
Onderzoeksproduct en/of interventie
Patients will receive biotinylated blood to be able to distinguish the donors blood from the patients own blood
Publiek
N.P. Juffermans
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 5662509
n.p.juffermans@amc.uva.nl
Wetenschappelijk
N.P. Juffermans
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 5662509
n.p.juffermans@amc.uva.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
- Patients must receive an erythrocyte transfusion on the ICU, to correct for anemia
- Patients may not have received a transfusion with red blood cells, plasma or thrombocytes in the previous 24 hours
- Patients may not receive more than 1 unit of RBCs
- Patients may not be suspected of having an active bleeding
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
- Patients who have not given informed consent
- Patients who pose difficulties in securing blood products (e.g. rare blood groups)
- Patients who receive more than 1 unit of RBCs in 1 transfusion episode
- No arterial catheter in situ
- Patients who received biotinylated blood before (earlier enrollment in TETRIS2)
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL6419 |
| NTR-old | NTR6596 |
| CCMO | NL61833.018.17 |
| OMON | NL-OMON48722 |